UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 31, 2006
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 000-32085 | 36-4392754 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
222 Merchandise Mart Plaza, Suite 2024, Chicago, IL 60654 |
||||
Registrants telephone number, including area code 1-800-654-0889.
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02. Results of Operations and Financial Condition.
On January 31, 2006, the registrant announced its earnings for the three months and year ended December 31, 2005. Further details are described in the press release issued by the registrant on January 31, 2006, and furnished as Exhibit 99.1 hereto and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
Exhibit No. |
Description of Exhibit | |
99.1 | Press release issued January 31, 2006 |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. | ||||
Date: January 31, 2006 |
By: |
/s/ William J. Davis | ||
William J. Davis | ||||
Chief Financial Officer |
INDEX TO EXHIBITS
Exhibit Number |
Description | |
99.1 | Press release issued January 31, 2006 |
Exhibit 99.1
Allscripts Contacts: Dan Michelson Chief Marketing Officer 312-506-1217 dan.michelson@allscripts.com |
Bill Davis Chief Financial Officer 312-506-1211 bill.davis@allscripts.com |
FOR IMMEDIATE RELEASE
Allscripts Reports Record Fourth Quarter 2005 Results
Net Income Increases More Than 200% For The Year
CHICAGO, IL January 31, 2006 Allscripts (Nasdaq: MDRX), the leading provider of clinical software, connectivity and information solutions that physicians use to improve healthcare, today announced results for the three months and year ended December 31, 2005.
Total revenue for the three months ended December 31, 2005 was $34.2 million, compared to $26.3 million for the same period last year. Revenue from software and related services for the three months ended December 31, 2005 was $18.2 million, compared to $14.3 million for the same period last year, increasing by 28%.
Gross margin percentage was 45.5% for the fourth quarter of 2005, compared to 46.9% during the fourth quarter of 2004.
Net income for the three months ended December 31, 2005 was $3.4 million, or $0.08 per diluted share, compared to net income of $1.4 million, or $0.03 per diluted share, for the same period last year, a net income increase of 143%. As previously disclosed, net income for the three months ended December 31, 2005 includes a non-cash, non-recurring stock-based compensation charge related to the acceleration of certain options amounting to approximately $0.5 million. Without this charge, diluted earnings per share for the fourth quarter 2005 would have been $0.09. A reconciliation of earnings per share excluding the option acceleration expense to GAAP earnings per share is included as part of this press release.
As of December 31, 2005, the Company had cash and marketable securities of $146.1 million.
In 2005, the market for clinical automation continued to accelerate as the electronic health record became part of the black bag of medicine. Allscripts played a leadership role in driving this transformation and our record results show that we continue to gain traction, stated Glen Tullman, Chief Executive Officer of Allscripts. The Company has never been better positioned and our pending acquisition of A4 Health Systems will result in Allscripts being the clear leader across all segments of the ambulatory market. I appreciate our clients continued support and am very proud of our team and the progress we made during the year towards our vision of becoming an indispensable part of the way physicians practice medicine.
Total revenue for the year ended December 31, 2005 was $120.6 million, compared to $100.8 million for 2004. Revenue from software and related services for the year ended December 31, 2005 was $65.2 million, compared to $44.1 million for 2004, increasing by 48%.
Total gross margin percentage was 45.5% for the year ended December 31, 2005, compared to 42.3% for the year ended December 31, 2004.
Net income for the year ended December 31, 2005 was $9.7 million, or $0.23 per diluted share, compared to net income of $3.1 million, or $0.07 per diluted share, for 2004, a net income increase of 212%. Without the option acceleration expense recognized in the fourth quarter of 2005, diluted earnings per share would have been $0.24 for 2005.
Allscripts offered the following general guidance related to 2006, excluding any potential impact from the proposed acquisition of A4 Health Systems. The Companys total revenue target for 2006 is expected to exceed $145 million. It anticipates that earnings per share will be in the range of $0.45 to $0.47 per diluted share, which excludes additional stock-based compensation expense.
Allscripts will conduct a conference call on Tuesday, January 31, 2006 at 4:30 PM eastern time. The conference call can be accessed by dialing 1-800-374-0526, or via the Internet at www.allscripts.com. A recording of the conference call will be available for review through February 14, 2006, at www.allscripts.com or by calling 1-800-642-1687, ID # 4715321.
About Allscripts
Allscripts is the leading provider of clinical software, connectivity and information solutions that physicians use to improve healthcare. The Companys business groups provide unique solutions that inform, connect and transform healthcare. The Clinical Solutions Groups award-winning clinical software applications include Electronic Health Record, e-prescribing and document imaging solutions. Additionally, Allscripts provides clinical product education and connectivity solutions for physicians and patients through its Physicians Interactive Group and medical fulfillment services through its Medication Services Group. To learn more, visit Allscripts on the Web at www.allscripts.com.
This announcement may contain forward-looking statements about Allscripts that involve risks and uncertainties, including statements involving our pending acquisition of A4 Health Systems, Inc. and guidance related to 2006. These statements are developed by combining currently available information with Allscripts beliefs and assumptions. Forward-looking statements do not guarantee future performance. Because Allscripts cannot predict all of the risks and uncertainties that may affect it, or control the ones it does predict, Allscripts actual results may be materially different from the results expressed in its forward-looking statements. For a more complete discussion of the risks, uncertainties and assumptions that may affect Allscripts, see the Companys 2004 Annual Report on Form 10-K, available through the Web site maintained by the Securities and Exchange Commission at www.sec.gov.
Allscripts Healthcare Solutions, Inc.
Condensed Consolidated Balance Sheets
(amounts in thousands)
(Unaudited)
December 31, 2005 |
December 31, 2004 | |||
Assets |
||||
Current assets: |
||||
Cash and cash equivalents |
$60,905 | $16,972 | ||
Marketable securities |
54,408 | 22,796 | ||
Accounts receivable, net |
29,244 | 21,382 | ||
Other receivables |
502 | 627 | ||
Inventories |
2,174 | 2,372 | ||
Prepaid expenses and other current assets |
5,811 | 3,571 | ||
Total current assets |
153,044 | 67,720 | ||
Long-term marketable securities |
30,750 | 88,471 | ||
Fixed assets, net |
2,753 | 2,366 | ||
Software development costs, net |
6,409 | 6,270 | ||
Intangible assets, net |
9,151 | 10,833 | ||
Goodwill |
13,760 | 13,713 | ||
Other assets |
5,097 | 4,804 | ||
Total assets |
$220,964 | $194,177 | ||
Liabilities and Stockholders Equity |
||||
Current liabilities: |
||||
Accounts payable |
$8,630 | $5,981 | ||
Accrued liabilities |
13,791 | 12,218 | ||
Deferred revenue |
17,306 | 14,607 | ||
Total current liabilities |
39,727 | 32,806 | ||
Long-term debt |
82,500 | 82,500 | ||
Other liabilities |
318 | 178 | ||
Total liabilities |
122,545 | 115,484 | ||
Stockholders equity |
98,419 | 78,693 | ||
Total liabilities and stockholders equity |
$220,964 | $194,177 | ||
Allscripts Healthcare Solutions, Inc.
Condensed Consolidated Statements of Operations
(amounts in thousands, except per-share amounts)
(Unaudited)
Three Months Ended December 31, |
For the Year Ended December 31, |
|||||||||||
2005 |
2004 |
2005 |
2004 |
|||||||||
Revenue: |
||||||||||||
Prepackaged medications |
$12,789 | $9,342 | $45,609 | $44,733 | ||||||||
Software and related services |
18,249 | 14,306 | 65,166 | 44,121 | ||||||||
Information services |
3,159 | 2,665 | 9,789 | 11,916 | ||||||||
Total revenue |
34,197 | 26,313 | 120,564 | 100,770 | ||||||||
Cost of revenue: |
||||||||||||
Prepackaged medications |
10,873 | 7,317 | 38,046 | 35,744 | ||||||||
Software and related services |
6,908 | 5,154 | 23,507 | 15,858 | ||||||||
Information services |
849 | 1,506 | 4,136 | 6,520 | ||||||||
Total cost of revenue |
18,630 | 13,977 | 65,689 | 58,122 | ||||||||
Gross profit |
15,567 | 12,336 | 54,875 | 42,648 | ||||||||
Operating expenses: |
||||||||||||
Selling, general and administrative expenses |
11,510 | 10,337 | 43,304 | 37,653 | ||||||||
Stock-based compensation expense |
558 | | 604 | | ||||||||
Amortization of intangibles |
436 | 441 | 1,744 | 1,752 | ||||||||
Income from operations |
3,063 | 1,558 | 9,223 | 3,243 | ||||||||
Interest expense |
(880 | ) | (884 | ) | (3,516 | ) | (1,717 | ) | ||||
Interest income |
1,230 | 802 | 4,128 | 1,675 | ||||||||
Other expense, net |
(10 | ) | (73 | ) | (125 | ) | (93 | ) | ||||
Income before income taxes |
3,403 | 1,403 | 9,710 | 3,108 | ||||||||
Income taxes |
| | | | ||||||||
Net income |
$3,403 | $1,403 | $9,710 | $3,108 | ||||||||
Net income per share - basic |
$0.08 | $0.04 | $0.24 | $0.08 | ||||||||
Net income per share - diluted |
$0.08 | $0.03 | $0.23 | $0.07 | ||||||||
Weighted average shares of common stock outstanding used in computing basic net income per share |
40,812 | 38,484 | 40,045 | 38,979 | ||||||||
Weighted average shares of common stock outstanding used in computing diluted net income per share |
43,890 | 41,439 | 43,068 | 41,592 | ||||||||
Earnings per share reconciliation: |
||||||||||||
Net income, as reported-GAAP (unaudited) |
$3,403 | $1,403 | $9,710 | $3,108 | ||||||||
Add: Stock-based compensation charge for acceleration of options |
518 | | 518 | | ||||||||
Net income excluding stock-based compensation charge |
$3,921 | $1,403 | $10,228 | $3,108 | ||||||||
Net income per share excluding stock-based compensation charge - basic |
$0.10 | $0.04 | $0.26 | $0.08 | ||||||||
Net income per share excluding stock-based compensation charge - diluted |
$0.09 | $0.03 | $0.24 | $0.07 | ||||||||